Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

AstraZeneca PLC ADR (AZN)

NASDAQ
Currency in USD
Disclaimer
68.26
+1.93(+2.91%)
Closed
Pre Market
68.05-0.21(-0.31%)

AZN Comments

Three vaccines are in Phase 3 clinical trials in the U.S. They are an AstraZeneca PLC vaccine developed with Oxford University, one from Moderna Inc., and a candidate from Pfizer Inc. and German-based BioNTech SE. AstraZeneca and Oxford University are conducting a Phase 3 study of their vaccine candidate in the U.K., South Africa and Brazil with several thousand volunteers. In a July conference call with reporters, AstraZeneca executives said results from that trial could be available sometime between September and November, depending on the severity of the pandemic in those countries. AstraZeneca said on the call that data from the study could be sufficient to gain emergency-use authorization in the U.S., if the data are strong enough. "We will be ready from a manufacturing viewpoint to start delivery," AstraZeneca Chief Executive Pascal Soriot said on the conference call. "The question is how quickly do we get a clinical readout and that's very much influenced by the infection rate
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.